Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene therapy platform based on its proprietary ministring DNA (msDNA) technology. A Toronto-based company Mediphage uses a proprietary manufacturing process to develop safe and redosable gene delivery vectors. msDNA is designed to overcome critical challenges facing viral gene therapies and leverage advancements in the delivery of nucleic acids.